Effect of ruboxistaurin on urinary transforming growth factor-β in patients with diabetic nephropathy and type 2 diabetes

Diabetes Care

Volumn 30, Issue 4, 2007, Pages 995-996

  Gilbert, Richard E ^a,b   Kim, Sandra A ^a   Tuttle, Katherine R ^c   Bakris, George L ^d   Toto, Robert D ^e   McGill, Janet B ^f   Haney, Douglas J ^g   Kelly, Darren J ^b   Anderson, Pamela W ^g  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c SACRED HEART MEDICAL CENTER   (United States)

^d UNIVERSITY OF CHICAGO   (United States)

^e UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^f WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PROTEIN KINASE B; RUBOXISTAURIN; TRANSFORMING GROWTH FACTOR BETA;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE URINE LEVEL; DIABETIC NEPHROPATHY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG MECHANISM; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; URINALYSIS;

EID: 34147151265     PISSN: 01495992     EISSN: 01495992     Source Type: Journal    
DOI: 10.2337/dc06-2079     Document Type: Article

References (20)

1. Way KJ, Katai N, King GL: Protein kinase C and the development of diabetic vascular complications. Diabet Med 18:945-959, 2001
2. Sheetz MJ, King GL: Molecular understanding of hyperglycemia's adverse effects for diabetic complications. JAMA 288:2579-2588, 2002
3. Setter SM, Campbell RK, Cahoon CJ: Biochemical pathways for microvascular complications of diabetes mellitus. Ann Pharmacother 37:1858-1866, 2003
4. He Z, King GL: Microvascular complications of diabetes. Endocrinol Metab Clin North Am 33:215-238, 2004
5. Schena FP, Gesualdo L: Pathogenetic mechanisms of diabetic nephropathy. J Am Soc Nephrol 16 (Suppl 1):S30-S33, 2005
6. Kelly DJ, Chanty A, Gow RM, Zhang Y, Gilbert RE: Protein kinase C beta inhibition attenuates osteopontin expression, macrophage recruitment, and tubulointerstitial injury in advanced experimental diabetic nephropathy. J Am Soc Nephrol 16:1654-1660, 2005
7. Sharma K, Ziyadeh FN: Hyperglycemia and diabetic kidney disease: the case for transforming growth factor-β as a key mediator. Diabetes 44:1139-1146, 1995
8. Sharma K, Ziyadeh FN, Alzahabi B, McGowan TA, Kapoor S, Kurnik BRC, Kurnik PB, Weisberg LS: Increased renal production of transforming growth factor-β1 in patients with type II diabetes. Diabetes 46:854-859, 1997
9. Gilbert RE, Akdeniz A, Allen TJ, Jerums G: Urinary transforming growth factorbeta in patients with diabetic nephropathy: implications for the pathogenesis of tubulointerstitial pathology. Nephrol Dial Transplant 16:2442-2443, 2001
10. Houlihan CA, Akdeniz A, Tsalamandris C, Cooper ME, Jerums G, Gilbert RE: Urinary transforming growth factor-β excretion in patients with hypertension, type 2 diabetes, and elevated albumin excretion rate: effects of angiotensin receptor blockade and sodium restriction. Diabetes Care 25:1072-1077, 2002
11. Tuttle KR, Bakris GL, Toto RD, McGill JB, Hu K, Anderson PW: The effect of ruboxistaurin on nephropathy in type 2 diabetes. Diabetes Care 28:2686-2690, 2005
12. Ellis D, Forrest KY, Erbey J, Orchard TJ: Urinary measurement of transforming growth factor-beta and type IV collagen as new markers of renal injury: application in diabetic nephropathy. Clin Chem 44:950-956, 1998
13. Nakamura T, Ushiyama C, Suzuki S, Hara M, Shimada N, Ebihara I, Koide H: Urinary excretion of podocytes in patients with diabetic nephropathy. Nephrol Dial Transplant 15:1379-1383, 2000
14. Wang S, Denichilo M, Brubaker C, Hirschberg R: Connective tissue growth factor in tubulointerstitial injury of diabetic nephropathy. Kidney Int 60:96-105, 2001
15. Gilbert RE, Akdeniz A, Weitz S, Usinger WR, Molineaux C, Jones SE, Langham RG, Jerums G: Urinary connective tissue growth factor excretion in patients with type 1 diabetes and nephropathy. Diabetes Care 26:2632-2636, 2003
16. Taft J, Nolan CJ, Yeung SP, Hewitson TD, Martin FIR: Clinical and histological correlations of decline in renal function in diabetic patients with proteinuria. Diabetes 43:1046-1051, 1994
17. Bader R, Bader E, Grung KE, Markensen-Haen S, Christ H, Bohle A: Structure and function of the kidney in diabetic glomerulosclerosis: correlations between morphological and functional parameters. Pathol Res Pract 167:204-216, 1980
18. Cordonnier DJ, Pinel N, Barro C, Maynard M, Zaoui P, Halimi S, Hurault de Ligny B, Reznic Y, Simon D, Bilous RW: Expansion of cortical interstitium is limited by converting enzyme inhibition in type 2 diabetic patients with glomerulosclerosis: the Diabiopsies Group. J Am Soc Nephrol 10:1253-1263, 1999
19. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345:851-860, 2001
20. Gilbert RE, Cox A, Wu LL, Allen TJ, Hulthen UL, Jerums G, Cooper ME: Expression of transforming growth factor-β1 and type IV collagen in the renal tubulointerstitium in experimental diabetes: effects of ACE inhibition. Diabetes 47: 414-422, 1998